Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 6:46 PM
Ignite Modification Date:
2025-12-25 @ 4:17 PM
NCT ID:
NCT03151057
Group ID:
EG000
Title:
Idelalisib 100mg
Description:
Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.
intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
Idelalisib 100 MG: 100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
Deaths Number Affected:
2
Deaths Number At Risk:
None
Serious Number Affected:
7
Serious Number At Risk:
9
Other Number Affected:
9
Other Number At Risk:
9
Study:
NCT03151057
Results Section:
NCT03151057
Adverse Events Module:
NCT03151057